Replies to post #3837 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Re: New, Improved NovoSeven

Apart from the pegylated-FVIIa that NVO is developing with NTEC, NVO is developing an enhanced FVIIa called NN1731 that is further along in development than the product licensed from NTEC. Please see #msg-18366299 and #msg-18366317. Regards, Dew

[DewDiligence]

NTEC Presents Preclinical Data on Peg-FVIIa

[Peg-FVIIa, currently in phase-1, is an attempt by NVO to counter the 2011 patent expiration of NovoSeven, which has become a $1B drug. Independently of NTEC, NVO is also working on NN1731, an analog of FVIIa in preclinical development (#msg-18366299).]

http://biz.yahoo.com/bw/070711/20070711005688.html?.v=1

>>
Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Wednesday July 11, 10:42 am ET

HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM: NTEC ) today announced that two poster presentations were presented with its collaborative partner, Novo Nordisk A/S, relating to GlycoPEGylated recombinant Factor VIIa at the XXIst Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland. The data presented demonstrates that GlycoPEGylation(TM) significantly prolongs the active half-life of rFVIIa. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.

The posters, which were co-authored by Novo Nordisk and Neose, are titled:

Development of long-acting rFVIIa derivatives by GlycoPEGylation(TM)

Effect of GlycoPEGylation(TM) on the pharmacokinetic properties of rFVIIa

The full poster presentations are available on the Neose corporate website at: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations

About Coagulation Factor VII

Factor VII/VIIa is used in the treatment of bleeding episodes and for the prevention of bleeding during surgery or invasive procedures in patients with congenital hemophilia with inhibitors to coagulation factors VIII or IX. The worldwide market for recombinant Factor VII was approximately $1 billion in 2006, with Novo Nordisk being the only participant.

About Neose Technologies, Inc.

Neose Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of next-generation therapeutic proteins that are competitive with best-in-class protein drugs currently on the market, on its own and through strategic partnerships. The lead candidates in its pipeline, NE-180 for use in the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure and GlycoPEG-GCSF for chemotherapy-induced neutropenia, target markets with aggregate sales in excess of $15 billion. For more information, please visit www.neose.com.
<<